Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published Evidence

  title={Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published Evidence},
  author={I. Jacobs and Danielle Petersel and Leah Isakov and S. Lula and K. Lea Sewell},
  pages={525 - 570}
  • I. Jacobs, Danielle Petersel, +2 authors K. Lea Sewell
  • Published 2016
  • Medicine
  • Biodrugs
  • BackgroundClinicians are required to assimilate, critically evaluate, and extrapolate information to support appropriate use of biosimilars across indications.ObjectivesThe objective of this study was to systematically collate all published data in order to assess the weight (quantity and quality) of available evidence for each molecule and inform and support healthcare decision-making in chronic inflammatory diseases.MethodsMEDLINE®, EMBASE®, and ISI Web of Science® were searched to September… CONTINUE READING
    37 Citations
    Biosimilars for the Treatment of Cancer: A Systematic Review of Published Evidence
    • 29
    • PDF
    Biosimilars: implications for rheumatoid arthritis therapy
    • 17
    Biosimilars for the treatment of psoriatic arthritis
    • 1
    • Highly Influenced
    Uptake of rheumatology biosimilars in the absence of forced switching
    • 8
    • PDF
    Worldwide perspective of biosimilars for psoriasis
    • B. Kirby
    • Medicine
    • The British journal of dermatology
    • 2017
    • 1
    The use of biosimilar medicines in oncology - position statement of the Brazilian Society of Clinical Oncology (SBOC)
    • G. S. Fernandes, C. Sternberg, +4 authors D. Araujo
    • Business, Medicine
    • Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
    • 2018
    • 8
    • PDF
    Reporting of quality attributes in scientific publications presenting biosimilarity assessments of (intended) biosimilars: a systematic literature review.


    Biosimilar monoclonal antibodies: the scientific basis for extrapolation
    • 21
    Biosimilars: Rationale and current regulatory landscape.
    • E. Olech
    • Medicine
    • Seminars in arthritis and rheumatism
    • 2016
    • 32
    • PDF
    Biosimilars in inflammatory bowel disease: ready for prime time?
    • F. Gomollon
    • Medicine
    • Current opinion in gastroenterology
    • 2015
    • 20
    Biosimilars in rheumatology: current perspectives and lessons learnt
    • 93
    Biosimilars in the therapy of inflammatory bowel diseases
    • 34
    Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease.
    • V. Annese, M. Vecchi
    • Medicine
    • Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
    • 2014
    • 39
    The challenge of indication extrapolation for infliximab biosimilars.
    • 129